Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01777776
Title Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications

melanoma

Therapies

Encorafenib

Encorafenib + Ribociclib

Age Groups: adult
Covered Countries USA | CAN

Additional content available in CKB BOOST